Synthesis and HIV-1 integrase inhibition of novel bis- or tetra-coumarin analogues

Chemical and Pharmaceutical Bulletin

Volumn 55, Issue 12, 2007, Pages 1740-1743

  Chiang, Chih Chia ^a   Mouscadet, Jean François ^b   Tsai, Hou Jen ^a   Liu, Chi Tsan ^c   Hsu, Ling Yih ^d  

^a NATIONAL DEFENSE UNIVERSITY   (Taiwan)

^b Ecole Normale Superieure de Cachan   (France)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d CHINA INSTITUTE OF TECHNOLOGY   (Taiwan)

Author keywords

Bis coumarin; Human immuno deficiency virus 1 integrase; Inhibitor; Tetra coumarin

Indexed keywords

3,3' [3,5 DI[(4 METHYLBENZOYL)OXY]BENZYLIDENE]BIS 4 HYDROXYCOUMARIN; 3,3' [4 [2 (4 ACETOXY)ETHOXY]BENZYLIDENE]BIS 4 HYDROXYCOUMARIN; 3,3' [4 [2 (4 METHYLBENZOYLOXY)ETHOXY]BENZYLIDENE]BIS 4 HYDROXYCOUMARIN; 3,3' [4 [BIS(2 ACETOXYETHYL)AMINO]BENZYLIDENE]BIS 4 HYDROXYCOUMARIN; 3,3' [4 [BIS[2 (4 BROMOBENZOYLOXY)ETHYL]AMINO]BENZYLIDENE]BIS 4 HYDROXYCOUMARIN; 3,3' [4 [BIS[2 (4 METHYLBENZOYLOXY)ETHYL]AMINO]BENZYLIDENE]BIS 4 HYDROXYCOUMARIN; 3,3' [[4 (4 METHOXYBENZOYL)OXY]BENZYLIDENE]BIS 4 HYDROXYCOUMARIN; 4 [BIS(4 HYDROXY 2 OXO 2H CHROMEN 3 YL)METHYL]N 4 TOLYLBENZAMIDE; 4 [BIS(4 HYDROXY 2 OXO 2H CHROMEN 3 YL)METHYL]PHENYL 4' [BIS(4 HYDROXY 2 OXO 2H CHROMEN 3 YL)METHYL]BENZOATE; 4 HYDROXYCOUMARIN DERIVATIVE; COUMARIN DERIVATIVE; INTEGRASE; NSC 158393; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50;

CHEMISTRY, PHYSICAL; COUMARINS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; OLIGONUCLEOTIDES; SPECTROPHOTOMETRY, INFRARED;

EID: 36849060113     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.55.1740     Document Type: Article

References (21)

1. Vandamme A. M., Van Vaerenbergh K., De Clercq E., Antiviral Chem. Chemother., 9, 187-203 (1998).
2. Pani A., Loi A. G., Mura M., Marceddu T., La Colla P., Marongiu M. E., Curr. Drug Targets Infect. Disord., 2, 17-32 (2002).
3. Neamati N., Expert Opin. Ther. Patents, 12, 709-724 (2002).
4. Chen I. J., Neamati N., MacKerell A. D., Jr., Curr. Drug Targets Infect. Disord., 2, 217-234 (2002).
5. Katz R. A., Skalka A. M., Ann. Rev. Biochem., 63, 133-173 (1994).
6. Rice P., Craigie R., Davies D. R., Curr. Opin. Struct. Biol., 6, 76-83 (1996).
7. Farnet C. M., Wang B., Lipford J. R., Bushman F. D., Proc. Natl. Acad. Sci. U.S.A., 93, 9742-9747 (1996).
8. Fesen M. R., Pommier Y., Leteurtre F., Hiroguchi S., Yung J., Kohn K. W., Biochem. Pharmacol., 48, 595-608 (1994).
9. LaFemina R. L., Graham P. L., LeGrow K., Hastings J. C., Wolfe A., Young S. D., Emini E. A., Hazuda D. J., Antimicrob. Agents Chemother., 39, 320-324 (1995).
10. Fesen M. R., Kohn K. W., Leteurtre F., Pommier Y., Proc. Natl. Acad. Sci. U.S.A., 90, 2399-2403 (1993).
11. Dupont R., Jeanson L., Mouscadet J. F., Cotelle P., Bioorg. Med. Chem. Lett., 11, 3175-3178 (2001).
12. Hazuda D. J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J. A., Espeseth A., Gabryelski L., Schleif W., Blau C., Miller M. D., Science, 287, 646-650 (2000).
13. Cooper D., Gatell J., Rockstroh J., Katlama C., Yeni P., Lazzarin A., Chen J., Isaacs R., Teppler H., Nguyen B., Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. Oral abstract 105LBa. http://www.retroconference.org/2007/Abstracts/30687.htm
14. Steigbigel R., Kumar P., Eron J., Schechter M., Markowitz M., Loufty M., Zhao J., Isaacs R., Nguyen B., Teppler H., Results of BENCHMRK-2, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. Oral abstract 105LBa. http://www.retroconference.org/2007/Abstracts/30688.htm
15. Mazumder A., Wang S., Neamati N., Nicklaus M., Sunder S., Chen J., Milne G. W., Rice W. G., Jr., Burke T. R., Pommier Y., J. Med. Chem., 39, 2472-2481 (1996).
16. Zhao H., Neamati N., Hong H., Mazumder A., Wang S., Sunder S., Milne G. W., Pommier Y., Jr., Burke T. R., J. Med. Chem., 40, 242-249 (1997).
17. Mao P. C. M., Mouscadet J. F., Leh H., Auclair C., Hsu L. Y., Heterocycles, 55, 1263-1270 (2001).
18. Mao P. C.-M., Mouscadet J.-F., Leh H., Auclair C., Hsu L. Y., Chem. Pharm. Bull., 50, 1634-1637 (2002).
19. Long Y.-Q., Jiang X.-H., Dayam R., Sanchez T., Shoemaker R., Sei S., Neamati N., J. Med. Chem., 47, 2561-2573 (2004).
20. Taddeo B., Haseltine W. A., Farnet C. M., J. Virol., 68, 8401-8405 (1994).
21. Mekouar K., Mouscadet J. F., Desmaele D., Subra F., Leh H., Savoure D., Auclair C., d'Angelo J., J. Med. Chem., 41, 2846-2857 (1998).